These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 10624968)
61. Critical temperature ranges of hypothermia-induced platelet activation: possible implications for cooling patients in cardiac surgery. Straub A; Breuer M; Wendel HP; Peter K; Dietz K; Ziemer G Thromb Haemost; 2007 Apr; 97(4):608-16. PubMed ID: 17393024 [TBL] [Abstract][Full Text] [Related]
62. Can the antiplatelet effects of cangrelor be reliably studied in mice under in vivo and in vitro conditions using flow cytometry? Kassassir H; Siewiera K; Sychowski R; Watała C Pharmacol Rep; 2013; 65(4):870-83. PubMed ID: 24145081 [TBL] [Abstract][Full Text] [Related]
63. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: discriminating abciximab and small molecular weight antagonists. Quinn M; Deering A; Stewart M; Cox D; Foley B; Fitzgerald D Circulation; 1999 May; 99(17):2231-8. PubMed ID: 10226086 [TBL] [Abstract][Full Text] [Related]
64. Human platelet activation is inhibited by the occupancy of glycoprotein IIb/IIIa receptor. Padoin E; Alexandre A; Cavallini L; Polverino de Laureto P; Rao GH; Doni MG Arch Biochem Biophys; 1996 Sep; 333(2):407-13. PubMed ID: 8809080 [TBL] [Abstract][Full Text] [Related]
65. The platelet fibrinogen receptor: an immunogold-surface replica study of agonist-induced ligand binding and receptor clustering. Isenberg WM; McEver RP; Phillips DR; Shuman MA; Bainton DF J Cell Biol; 1987 Jun; 104(6):1655-63. PubMed ID: 3584243 [TBL] [Abstract][Full Text] [Related]
66. Cardiopulmonary bypass leads to a preferential loss of activated platelets. A flow cytometric assay of platelet surface antigens. Wahba A; Black G; Koksch M; Rothe G; Preuner J; Schmitz G; Birnbaum DE Eur J Cardiothorac Surg; 1996; 10(9):768-73. PubMed ID: 8905280 [TBL] [Abstract][Full Text] [Related]
67. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Smith JW; Steinhubl SR; Lincoff AM; Coleman JC; Lee TT; Hillman RS; Coller BS Circulation; 1999 Feb; 99(5):620-5. PubMed ID: 9950658 [TBL] [Abstract][Full Text] [Related]
68. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model. Kondo N; Suzuki Y; Wakayama F; Tamai Y; Ji K; Fukui K; Fukuda I Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376 [TBL] [Abstract][Full Text] [Related]
69. Effects of extracorporeal circulation and heparin on the phenotype of platelet surface antigens following heart surgery. Wahba A; Rothe G; Lodes H; Barlage S; Schmitz G; Birnbaum DE Thromb Res; 2000 Mar; 97(6):379-86. PubMed ID: 10704646 [TBL] [Abstract][Full Text] [Related]
70. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome. Yakushkin VV; Zyuryaev IT; Khaspekova SG; Sirotkina OV; Ruda MY; Mazurov AV Platelets; 2011; 22(4):243-51. PubMed ID: 21329420 [TBL] [Abstract][Full Text] [Related]
71. Differential effect of the GPIIb/IIIa antagonist orbofiban on human platelet aggregate formation in vitro. Racanelli AL; Gibbs SK; Zondlo SC; Seiffert DA; Friedman SM; Feuerstein GZ Thromb Res; 2003 May; 110(2-3):99-105. PubMed ID: 12893024 [TBL] [Abstract][Full Text] [Related]
72. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa]. Khaspekova SG; Vyzova TV; Lukin VV; Tikhomirov OIu; Berndt M; Kouns W; Mazurov AV Biokhimiia; 1996 Mar; 61(3):412-28. PubMed ID: 8724599 [TBL] [Abstract][Full Text] [Related]
73. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. Quinn MJ; Cox D; Foley JB; Fitzgerald DJ J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104 [TBL] [Abstract][Full Text] [Related]
74. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation. Day JR; Haskard DO; Taylor KM; Landis RC Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862 [TBL] [Abstract][Full Text] [Related]
75. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Horstrup K; Jablonka B; Hönig-Liedl P; Just M; Kochsiek K; Walter U Eur J Biochem; 1994 Oct; 225(1):21-7. PubMed ID: 7925440 [TBL] [Abstract][Full Text] [Related]
76. Preparation and pharmacological evaluation of novel glycoprotein (Gp) IIb/IIIa antagonists. 1. The selection of naphthalene derivatives. Ono S; Inoue Y; Yoshida T; Ashimori A; Kosaka K; Imada T; Fukaya C; Nakamura N Chem Pharm Bull (Tokyo); 1999 Dec; 47(12):1685-93. PubMed ID: 10748713 [TBL] [Abstract][Full Text] [Related]
77. Normal ADP-induced aggregation and absence of dissociation of the membrane GP IIb-IIIa complex of intact rat platelets pretreated with EDTA. Gachet C; Stierlé A; Ohlmann P; Lanza F; Hanau D; Cazenave JP Thromb Haemost; 1991 Aug; 66(2):246-53. PubMed ID: 1771618 [TBL] [Abstract][Full Text] [Related]
78. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Gries A; Bode C; Peter K; Herr A; Böhrer H; Motsch J; Martin E Circulation; 1998 Apr; 97(15):1481-7. PubMed ID: 9576429 [TBL] [Abstract][Full Text] [Related]
79. Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial? Serebruany V; Malinin A; Pokov A; Arora U; Atar D; Angiolillo D Thromb Res; 2007; 119(2):175-81. PubMed ID: 16546241 [TBL] [Abstract][Full Text] [Related]
80. Temperature-dependent effects of EDTA on the membrane glycoprotein IIb-IIIa complex and platelet aggregability. Pidard D; Didry D; Kunicki TJ; Nurden AT Blood; 1986 Mar; 67(3):604-11. PubMed ID: 3004616 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]